STOCK TITAN

Fortress Biotech (NASDAQ: FBIO) reports 2026 director and auditor vote tallies

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Fortress Biotech reported the results of its 2026 annual meeting of stockholders held virtually on June 17. Stockholders voted on electing seven directors to serve until the 2027 meeting and on ratifying KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.

Each director nominee, including Lindsay A. Rosenwald, Jimmie Harvey Jr., Malcolm Hoenlein, Dov Klein, J. Jay Lobell, Kevin L. Lorenz, and Michael S. Weiss, received more votes "For" than "Against." The proposal to ratify KPMG LLP also received substantially more votes "For" than "Against," based on the reported vote totals.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Votes for Rosenwald 11,022,326 votes Director Lindsay A. Rosenwald election at 2026 annual meeting
Votes for Jimmie Harvey Jr. 10,322,230 votes Director election at 2026 annual meeting
Total votes per director 12,897,124 votes Total votes including broker non-votes for each director nominee
Votes for KPMG ratification 23,095,864 votes Proposal to ratify KPMG LLP for year ending December 31, 2026
Votes against KPMG ratification 753,612 votes Auditor ratification proposal at 2026 annual meeting
Abstentions on KPMG ratification 341,934 votes Auditor ratification proposal at 2026 annual meeting
annual meeting of stockholders financial
"held its annual meeting of stockholders (the “2026 Annual Meeting”)"
independent registered public accounting firm financial
"the ratification of the appointment of KPMG LLP as Fortress’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
broker non-votes financial
"Total Votes ... Broker Non-"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
definitive proxy statement regulatory
"The proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
0001429260false0001429260us-gaap:CommonStockMember2026-06-172026-06-170001429260fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember2026-06-172026-06-1700014292602026-06-172026-06-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 17, 2026

Fortress Biotech, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
 (State or Other Jurisdiction
of Incorporation)

  ​ ​

001-35366
 (Commission File Number)

  ​ ​ ​

20-5157386
(IRS Employer
Identification No.)

1111 Kane Concourse, Suite 301

Bay Harbor IslandsFL 33154

(Address of Principal Executive Offices)

(781652-4500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act.

Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

FBIO

Nasdaq Capital Market

9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

FBIOP

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 17, 2026, Fortress Biotech, Inc. (the “Company” or “Fortress”) held its annual meeting of stockholders (the “2026 Annual Meeting”) at 10:00 a.m. Eastern Time by means of an online virtual meeting platform.

 

At the 2026 Annual Meeting, the following two proposals were voted on by the stockholders: (i) the election of seven directors to hold office until the 2027 annual meeting of stockholders or until such director resigns or is removed from office; and (ii) the ratification of the appointment of KPMG LLP as Fortress’s independent registered public accounting firm for the year ending December 31, 2026. The proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A for the 2026 Annual Meeting filed with the Securities and Exchange Commission on April 28, 2026.

Proposal 1

 

The votes with respect to the election of seven directors to hold office until the 2027 annual meeting of stockholders were as follows:

 

Total Votes

Broker Non-

Director

Total Votes For

  ​ ​ ​

Against

  ​ ​ ​

Abstentions

  ​ ​ ​

Votes

Lindsay A. Rosenwald, M.D.

 

11,022,326

239,772

32,188

12,897,124

Jimmie Harvey, Jr., M.D.

 

10,322,230

923,184

48,872

12,897,124

Malcolm Hoenlein

 

10,309,261

932,328

52,697

12,897,124

Dov Klein, CPA

 

10,323,030

931,434

39,822

12,897,124

J. Jay Lobell

9,756,949

1,313,658

223,679

12,897,124

Kevin L. Lorenz, J.D.

10,131,410

939,137

223,739

12,897,124

Michael S. Weiss

10,961,271

270,249

62,766

12,897,124

Proposal 2

 

The vote with respect to the ratification of the selection of KPMG LLP as Fortress’s independent registered accounting firm for the year ending December 31, 2026 was as follows:

  

Total Votes For

Total Votes Against

Abstentions

23,095,864

753,612

341,934

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Fortress Biotech, Inc.

(Registrant)

Date: June 23, 2026

 

By:

/s/ David Jin

 

 

David Jin

 

 

Chief Financial Officer

FAQ

What did Fortress Biotech (FBIO) vote on at the 2026 annual meeting?

Fortress Biotech stockholders voted on two items: electing seven directors to serve until the 2027 annual meeting and ratifying KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2026, as described in the company’s definitive proxy statement.

Were Fortress Biotech’s director nominees supported by stockholders at the 2026 meeting?

All seven director nominees received more votes "For" than "Against." For example, Lindsay A. Rosenwald received 11,022,326 votes for versus 239,772 against, while other nominees showed similar patterns of support based on the reported voting results in the meeting disclosure.

How did Fortress Biotech (FBIO) stockholders vote on the KPMG LLP auditor ratification?

Stockholders cast 23,095,864 votes "For" ratifying KPMG LLP as independent registered accounting firm, compared with 753,612 votes "Against" and 341,934 abstentions. The "For" votes substantially exceeded votes against, indicating strong support for retaining KPMG LLP for the 2026 fiscal year audit.

How many total votes were recorded for Fortress Biotech’s director elections?

For each director nominee, total votes reported were 12,897,124 including broker non-votes. Within this total, each nominee, such as Michael S. Weiss and Lindsay A. Rosenwald, received a majority of votes "For" compared with votes "Against" and abstentions in the tabulated results.

When and how was the 2026 Fortress Biotech annual meeting held?

The 2026 annual meeting of Fortress Biotech stockholders took place on June 17, 2026, at 10:00 a.m. Eastern Time. It was conducted as an online virtual meeting, allowing shareholders to participate and vote through a virtual meeting platform rather than an in-person gathering.

Filing Exhibits & Attachments

4 documents